Please login to the form below

Not currently logged in
Email:
Password:

Former Pfizer R&D head LaMattina to advise Ziarco

He previously spent 30 years at US pharma firm

Dr John LaMattina ZiarcoUK-based biotech Ziarco has hired former head of R&D at Pfizer, Dr John LaMattina, as a strategic R&D adviser.

Dr LaMattina spent 30 years at Pfizer in total, including four years as president of global research and development from 2003 until his retirement from the US pharma giant in 2007.

Earlier roles he held at Pfizer included senior VP of worldwide development and chief medical officer.

In his new role, he will help Ziarco to advance its development strategies for its investigational compounds to tackle inflammatory and allergic diseases.

These include a H4 agonist that has just completed a phase I study.

In addition to his role at Ziarco, LaMattina is a senior partner at PureTech Venues and serves on the board of directors at Ligand Pharmaceuticals and the scientific advisory board of Trevena Pharmaceuticals.

20th March 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics